Results 1 to 10 of about 11,332,305 (264)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer   +10 more
doaj   +8 more sources

Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer’s Disease and Cerebral Amyloid Angiopathy [PDF]

Biomolecules
Background: Amyloid-related imaging abnormalities (ARIA) have gained significance in the context of anti-amyloid therapies (AATs), exhibiting clinical and radiological manifestations that overlap with Cerebral Amyloid Angiopathy-related inflammation (CAA-
Marialuisa Zedde, Mattia Losa, Elena Grisafi, Davide D. Lucia, Ilaria Gandoglia, Massimo Del Sette, Matteo Pardini, Luca Roccatagliata, Rosario Pascarella, Fabrizio Piazza   +9 more
doaj   +3 more sources

Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment [PDF]

Pharmaceuticals
Background: Anti-amyloid therapies (AAT) are reshaping the therapeutic landscape of Alzheimer’s disease (AD), yet their implementation remains constrained by the risk of amyloid-related imaging abnormalities (ARIA).
Marialuisa Zedde, Mattia Losa, Andrea Donniaquio, Ilaria Gandoglia, Massimo Del Sette, Luca Roccatagliata, Fabrizio Piazza, Matteo Pardini, Rosario Pascarella   +8 more
doaj   +4 more sources

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed with anti‐amyloid therapies in Alzheimer's disease.
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Szofia Bullain, Paul Delmar, Gregory Klein, Marco Lyons, Fabrizio Piazza, Roxana O. Carare, Norman A. Mazer   +11 more
doaj   +3 more sources

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 [PDF]

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +4 more sources

Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side ...
Steven M. Greenberg, Costantino Iadecola, Sherry H.‐Y. Chou, Petrice M. Cogswell, Mitchell S. V. Elkind, William J. Hicks, Caitlin Le, Deborah A. Levine, Richard Lipton, Lauren Massimo, Stephanie M. Mohl, Sudha Seshadri, Heather M. Snyder, Kristine Yaffe, Kori S. Zachrison   +14 more
doaj   +2 more sources

Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA) [PDF]

Alzheimer’s Research & Therapy
Introduction Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer’s disease (AD), yet real-world data is needed to optimize patient selection and enhance safety monitoring, particularly
Noa Bregman, Nuno Pedrosa de Barros, Talya Nathan, Mori Hay Levy, Diana Sima, Simon Van Eyndhoven, Aya Bar-David, Orna Aizenstein, Dana Niry, Lilian Atlan, Anan Abu Awad, Elissa Ash, Nurit Omer, Tamara Shiner   +13 more
doaj   +2 more sources

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities ...
Alexander Wallace, Oliver Zhou, Minh‐Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall   +5 more
doaj   +2 more sources

Amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease: from pathophysiology to individualized risk assessment [PDF]

Alzheimer’s Research & Therapy
Monoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer’s disease, they are associated ...
Jonathan Merkel, Robert Perneczky, Frank Jessen, Lutz Frölich, Olav Jansen, Sönke Peters, Daniela Berg, Jörg B. Schulz, Thorsten Bartsch   +8 more
doaj   +2 more sources

Amyloid‐related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid‐modifying therapy [PDF]

Annals of Clinical and Translational Neurology
Amyloid‐related imaging abnormalities, were originally described by dementia care experts. The wider use of aducanumab and now lecanemab warrant broader understanding by the health care provider continuum.
Rade B. Vukmir
doaj   +2 more sources